Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for MYGN
+1.02 (3.50%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.08 - 30.27
52 week 17.50 - 41.57
Open 29.12
Vol / Avg. 1.43M/739,482.00
Mkt cap 2.11B
P/E 16.36
Div/yield     -
EPS 1.84
Shares 69.85M
Beta 0.44
Inst. own 107%
Apr 30, 2018
Q3 2018 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 13, 2018
Myriad Genetics Inc at Cowen Health care Conference
Feb 6, 2018
Q2 2018 Myriad Genetics Inc Earnings Call - Webcast
Feb 6, 2018
Q2 2018 Myriad Genetics Inc Earnings Release
Jan 8, 2018
Myriad Genetics Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 16.55% 2.80%
Operating margin 2.27% 6.40%
EBITD margin - 12.67%
Return on average assets 10.48% 2.05%
Return on average equity 14.43% 2.86%
Employees 2,400 -
CDP Score - -


320 S Wakara Way
SALT LAKE CITY, UT 84108-1214
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark S. Verratti President-President Assurex Health
Age: 47
Bio & Compensation  - Reuters
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
R. Bryan Riggsbee CPA Chief Financial Officer, Treasurer
Age: 46
Bio & Compensation  - Reuters
Alexander Ford President of Myriad Genetic Laboratories, Inc.
Age: 50
Bio & Compensation  - Reuters
Ralph L. McDade Ph.D. President of Myriad RBM, Inc
Age: 62
Bio & Compensation  - Reuters
Bernard F. Tobin President of Crescendo Bioscience, Inc
Age: 55
Bio & Compensation  - Reuters
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 61
Bio & Compensation  - Reuters